High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: Angioscopic comparison with sirolimus-eluting stent - 05/08/11
, Masami Nishino, MD, Masayuki Taniike, MD, Nobuhiko Makino, MD, Hiroyasu Kato, MD, Yasuyuki Egami, MD, Ryu Shutta, MD, Hitoshi Yamaguchi, MD, Jun Tanouchi, MD, Yoshio Yamada, MDRésumé |
Background |
Difference of neointimal formational pattern and incidence of thrombus formation between sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) at 18 months after stent implantation has not previously been reported.
Methods |
We retrospectively enrolled 35 event-free patients who received SES (15 patients, 18 stents) or PES (20 patients, 23 stents) implantation with 18-month follow-up coronary angioscopy. We divided our patients into SES or PES groups and compared neointimal coverage pattern and incidence of red mural thrombus formation between the 2 groups. Neointimal coverage grades were classified into 4 categories. Minimum neointimal coverage grade, maximum grade, and heterogeneity score were assessed in each stent. Heterogeneity score was calculated by subtracting minimum from maximum grade within one stent.
Results |
Minimum neointimal coverage grade of PES was significantly lower than that of SES (0.70 ± 0.64 vs 1.33 ± 0.69, P = .005), whereas maximum grade was not significantly different (2.48 ± 0.73 vs 2.22 ± 0.73, P = .218). Heterogeneity score and incidence of red mural thrombus of PES were higher than those of SES (1.78 ± 0.80 vs 0.89 ± 0.76, P = .002 and 70% vs 11%, P < .001).
Conclusions |
The present study revealed that PES shows more heterogeneous neointimal coverage and higher incidence of thrombus formation as compared with SES at 18 months after stent implantation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 159 - N° 5
P. 905-910 - mai 2010 Retour au numéro
Article précédent
- Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
- Osama Alhadramy, Cynthia M. Westerhout, Sorin J. Brener, Christopher B. Granger, Paul W. Armstrong, for the APEX AMI Investigators
- Cardiac magnetic resonance assessment of left and right ventricular morphologic and functional adaptations in professional soccer players
- Michael Scharf, Matthias H. Brem, Matthias Wilhelm, Uwe Joseph Schoepf, Michael Uder, Michael M. Lell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?